BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38513538)

  • 1. The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.
    Wallace ND; Alexander M; Xie J; Ball D; Hegi-Johnson F; Plumridge N; Siva S; Shaw M; Harden S; John T; Solomon B; Officer A; MacManus M
    Lung Cancer; 2024 Apr; 190():107531. PubMed ID: 38513538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
    Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
    J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of current versus former smoking status on the outcomes of non-metastatic non-small cell lung cancer treated with upfront surgery; findings from the National Lung Screening Trial.
    Abdel-Rahman O
    Expert Rev Respir Med; 2019 Jun; 13(6):585-591. PubMed ID: 31055993
    [No Abstract]   [Full Text] [Related]  

  • 6. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
    Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
    Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
    Guo MZ; Murray JC; Ghanem P; Voong KR; Hales RK; Ettinger D; Lam VK; Hann CL; Forde PM; Brahmer JR; Levy BP; Feliciano JL; Marrone KA
    Clin Lung Cancer; 2022 Nov; 23(7):620-629. PubMed ID: 36045016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.
    Meguid RA; Hooker CM; Harris J; Xu L; Westra WH; Sherwood JT; Sussman M; Cattaneo SM; Shin J; Cox S; Christensen J; Prints Y; Yuan N; Zhang J; Yang SC; Brock MV
    Chest; 2010 Sep; 138(3):500-9. PubMed ID: 20507946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
    Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
    Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lungs don't forget: Comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.
    Varghese AM; Sima CS; Chaft JE; Johnson ML; Riely GJ; Ladanyi M; Kris MG
    J Thorac Oncol; 2013 Jan; 8(1):123-5. PubMed ID: 23242442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Smoking on Outcomes of HPV-related Oropharyngeal Cancer Treated with Primary Radiation or Surgery.
    Vawda N; Banerjee RN; Debenham BJ
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1125-1131. PubMed ID: 30513378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status.
    Kerrigan K; Wang X; Haaland B; Adamson B; Patel S; Puri S; Akerley W
    Clin Lung Cancer; 2021 Jul; 22(4):260-267.e2. PubMed ID: 33678584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort.
    Ferketich AK; Niland JC; Mamet R; Zornosa C; D'Amico TA; Ettinger DS; Kalemkerian GP; Pisters KM; Reid ME; Otterson GA
    Cancer; 2013 Feb; 119(4):847-53. PubMed ID: 23023590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
    Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
    Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.
    Tsao AS; Liu D; Lee JJ; Spitz M; Hong WK
    Cancer; 2006 Jun; 106(11):2428-36. PubMed ID: 16634096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
    J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
    Popat S; Liu SV; Scheuer N; Gupta A; Hsu GG; Ramagopalan SV; Griesinger F; Subbiah V
    JAMA Netw Open; 2022 May; 5(5):e2214046. PubMed ID: 35612853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
    Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
    Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.